FCH
MRNA icon

Freestone Capital Holdings’s Moderna MRNA Stock Holding History

Freestone Capital Holdings’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Buy
4,770
+801
+20% +$41.4K 0.01% 464
2026
Q1 		$202K Sell
3,969
-24,952
-86% -$1.16M 0.01% 517
2025
Q4 		$853K Sell
28,921
-2,990
-9% -$81.2K 0.03% 261
2025
Q3 		$824K Buy
31,911
+5,028
+19% +$140K 0.03% 266
2025
Q2 		$742K Sell
26,883
-2,003
-7% -$52.7K 0.03% 248
2025
Q1 		$782K Buy
+28,886
New +$1.03M 0.03% 234
2021
Q4 		– Sell
-2,109
Closed -$315K – 522
2021
Q3 		$315K Buy
+2,109
New +$778K 0.02% 340
2021
Q1 		– Sell
-2,410
Closed -$117K – 836
2020
Q4 		$117K Buy
2,410
+2,260
+1,507% +$229K 0.01% 411
2020
Q3 		$10.6K Buy
+150
New +$10.5K ﹤0.01% 732

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Freestone Capital Holdings's MRNA Position: Q2 2026 in Review

Freestone Capital Holdings increased its Moderna (MRNA) stake by 20% in Q2 2026, buying an estimated $41.4K and bringing the position to 4,770 shares worth $334K. The position accounts for 0.01% of the portfolio, ranked #464.

Freestone Capital Holdings first reported a position in MRNA in Q3 2020 and has held it in 9 quarters since. The position peaked at $853K in Q4 2025. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Freestone Capital Holdings held 4,770 shares of Moderna worth $334K as of Q2 2026.
  • Freestone Capital Holdings bought 801 Moderna shares in Q2 2026, an estimated $41.4K.
  • Moderna made up 0.01% of Freestone Capital Holdings's portfolio in Q2 2026, its #464 holding.
  • Freestone Capital Holdings first reported a position in Moderna in Q3 2020 and has held it in 9 quarters since.
  • Freestone Capital Holdings's Moderna position peaked at $853K in Q4 2025.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.